Research suggests that tumor exosomes from cells with a specific genetic fusion, PTPRZ1-MET, may contribute to a malignant phenotype and resistance to a certain chemotherapy, temozolomide, in glioblastoma. The role of exosomes in cancer is a subject of ongoing study, with potential implications for targeted therapies and liquid biopsies. The relationship between exosomes and chemotherapy resistance is also being explored in various types of cancer, including gliomas.